Overview

Prevention of Hepatitis B Virus Vertical Transmission by Serovaccination and Tenofovir During Pregnancy

Status:
Completed
Trial end date:
2016-07-01
Target enrollment:
Participant gender:
Summary
The risk of vertical HBV transmission is related to HBV DNA level in pregnant women, around 30% in women with HBV DNA above 1, 000 000 I.U/mL despite serovaccination of newborns. Using tenofovir DF during the last trimester of pregnancy allows to reduce the risk, but data from Western countries are needed.
Phase:
Phase 4
Details
Lead Sponsor:
Hopital Lariboisière
Treatments:
Tenofovir